← Leaderboards
David C Zhu
Ut Southwestern Medical Center
$6,236,143
Attributed
$19,537,173
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2017–25$10M$7.5M$5M$2.5M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,537,173 · 5
By mechanism
R01$16,222,194 · 3
RF1$2,600,455 · 1
R56$714,524 · 1
Top collaborators
- Rong Zhang18 shared
- Wanpen Vongpatanasin12 shared
- Kan Ding3 shared
- Dwight C. German3 shared
- Ann Marie Stowe3 shared
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Lina F Chalak$3,814,225
- Diana R Kerwin$2,377,168
- Colin Munro Cullum$3,167,533
- Hanzhang Lu$32,875,389
- David Richard Busch$3,894,467
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposS DiseaseBrainBlood PressureS Disease RiskDementiaCerebrovascular CirculationImpaired CognitionMagnetic Resonance ImagingAgingTau ProteinsHypertensionPerfusionCerebrovascularWhite MatterCerebrovascular DisordersEnrollmentRandomizedRestFunctional Magnetic Resonance ImagingAmyloid Beta-ProteinCardiovascular DiseasesAdultS Disease Related Dementia
Grant awards (18)
Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study)$2,316,231
R01 · FY2025 · AG
Cerebral Autoregulation, Brain Perfusion, and Neurocognitive Outcomes After Traumatic Brain Injury (CAPCOG-TBI)$1,161,635
R01 · FY2025 · NS
Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study)$2,372,741
R01 · FY2024 · AG
Cerebral Autoregulation, Brain Perfusion, and Neurocognitive Outcomes After Traumatic Brain Injury (CAPCOG-TBI)$1,146,429
R01 · FY2024 · NS
Diversity Supplement for Jenny Lutshumba$302,626
RF1 · FY2024 · AG
Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study)$69,318
R01 · FY2024 · AG
Biomarkers to Track Effective Interventions that Delay Dementia Onset in Participants of the "Risk Reduction for Alzheimer's Disease (rrAD)" Trial$2,297,829
RF1 · FY2023 · AG
Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study)$2,291,354
R01 · FY2023 · AG
Cerebral Autoregulation, Brain Perfusion, and Neurocognitive Outcomes After Traumatic Brain Injury (CAPCOG-TBI)$839,689
R01 · FY2023 · NS
Diversity Supplement to "Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study)"$69,274
R01 · FY2023 · AG
Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study)$2,369,453
R01 · FY2022 · AG
Hypertension, intracranial pulsatility and brain A-beta accumulation in older adults$743,929
R01 · FY2021 · AG
Biomarkers to track effective interventions that delay dementia onset in participants of the "Risk Reduction for Alzheimer's Disease (rrAD)" trial$714,524
R56 · FY2021 · AG
Hypertension, intracranial pulsatility and brain A-beta accumulation in older adults$672,027
R01 · FY2020 · AG
Diversity Supplement to "Hypertension, intracranial pulsatility and brain Aβ accumulation in older adults"$71,969
R01 · FY2020 · AG
Hypertension, intracranial pulsatility and brain A-beta accumulation in older adults$694,725
R01 · FY2019 · AG
Hypertension, intracranial pulsatility and brain A-beta accumulation in older adults$694,766
R01 · FY2018 · AG
Hypertension, intracranial pulsatility and brain A-beta accumulation in older adults$708,654
R01 · FY2017 · AG